Current Trading Halts . July 6 (Reuters) - Recce Pharmaceuticals Ltd: * SEEKS TRADING HALT PENDING ANNOUNCEMENT ON MATERIAL RESEARCH AGREEMENT Source text ⦠Once trading resumed Recce Pharmaceuticals came out ⦠A positive result would most certainly lift the SP considerably and I don't think RCE would have trouble raising the capital needed for phase 2 studies. The rest of the trading day saw price remaining in the range of 3.30-3.33p. It seems fairly clear the trading halt is because they have recieved a response to the request for HREC approval to begin phase 1 trial of topical skin use. Learn about investing with our Investing Education hub. Quotes. Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program This represents a sizeable 20% discount to its last close price. ASX:RCE - Investor presentation, announcements, cashflow waterfall chart, news, capital raise history, & sector peers. Happy days! It’s been a big month for the company, being placed in a trading halt at the start of the month. Likes. This study tested the R327 and R529 drugs against the COVID-19 virus and results showed that both showed increasing efficacy as the doses increased. Our Top 5 Stocks for Investors 50 or Older – NOW AVAILABLE! You can do it. Individual Investor Institutional Investor Financial Advisor Active Trader. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. Recce’s Chief Executive Officer, James Graham, commented: “We greatly appreciate the support shown by both our existing investors and new institutional investors. Sector Healthcare RiskRating. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. Thank you! It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE ⦠Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Finally closing at 3.3p (-4.35% from Monday's closing price). The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising. Breaking News. event.preventDefault(); Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product; The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program All Instrument Types. The coming months will soon reveal whether investors were right to back this one. All Instrument Types. Quotes. Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. BRIEF-Recce Pharmaceuticals Ltd Seeks Trading Halt . The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from its trading halt on Tuesday and is shooting higher. Find the investing style that's right for you. Pause Threshold Price. They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. How Much Money Do I Need To Start Investing? The Motley Fool Australia operates under AFSL 400691. Investment news, stock ideas, and more, straight to your inbox. Recce Pharmaceuticals is up a healthy 3.06 per cent trading at $1.01; Reccce Pharamceuticals (RCE) has become a dual-lister after assuming its position on a major German exchange. BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement . Financial Services Guide | Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Recce Pharmaceuticals. Breaking News. Based on these results Recce has been advised it should advance research of both drugs.
document.querySelector(this.getAttribute('href')).scrollIntoView({ Hear our experts take on shares, the market & how to invest. This ensures it is fully funded to complete its Phase I human clinical trial, SARSCoV-2 (COVID-19) pre-clinical program, Helicobacter pylori preclinical program, and the anticipated Phase I/II topical study at a leading Australian teaching hospital. So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered! Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. /*document.querySelectorAll('a[href^="#"]').forEach(anchor => { Individual Investor Institutional Investor Financial Advisor Active Trader. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. The Motley Fool Australia does not guarantee the performance of, or returns on any investment. Read detailed company information and latest announcements from Recce Pharmaceuticals Ltd including news headlines & gain/loss. Despite its share price weakness today, the Recce share price is up over 360% since the start of the year. The approval is not to sell anything or to allow general use anywhere, it is purely the approval they have been waiting for to start this skin application trial. Juno Minerals (JNO), a new company made up of Jupiter Mines’ demerged iron ore assets, has made its debut on the ASX. REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria. Be the first with the news that moves the market, ASX Today: Rebound to continue despite ore dive, Infinity Lithium Corporation (ASX:INF) shares crash amid Spanish permit cancellation, The “gas-fired” investment opportunity in the Australian energy sector, Imugene (ASX:IMU) expands patent portfolio with City of Hope, Province Resources (ASX:PRL) enters trading halt ahead of fresh capital raise, AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract, Great Northern Minerals’ (ASX:GNM) shares jump on high-grade results from Camel Creek, Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising, The company's shares will remain paused until the earlier of September 23 or when the announcement is made, On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase 1 clinical study of its RECCE 327 antibiotic, REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria, This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327, Shares in Recce last traded for $1.64 on September 18. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. Home / Share Market News / Share Fallers / Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, James Mickleboro | September 23, 2020 12:29pm | More on: RCE. Itâs been a big month for the company, being placed in a trading halt at the start of the month. The company's shares will remain in a trading halt until the earlier of September 23, or when the announcement is made. Audeara (AUA) has finished its first full trading on the ASX, after carrying out a successful $7 million initial public offering (IPO). Terms of Service | Subscription Terms of Service, ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691, The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214, jQuery(document).on('click', 'a[href^="#"]', function (event) { Shares in Recce Pharmaceuticals are currently trading at A$1.11 and the price has moved by 0.127k% over the past 365 days. Equus Mining (EQE) has placed its shares in a trading halt while it plans an upcoming capital raising. Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials. Happy days! The Motley Fool has a disclosure policy. Our latest articles and strategies for the post-work life you want. On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme; Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13; Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute. RCE Share Price and Trading History RELATED STOCKHEAD STORIES
jQuery('html, body').animate({ Speculative. Past performance is not necessarily indicative of future returns. }); As trading continued in the morning, price bounced off of the 3.3p support twice. Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Join Our Premium Community The Complete Guide to Planning For Your Retirement, Setting up an SMSF: 10 Things You Need to Know Before Starting, 3 easy steps to building your ASX share portfolio for an early retirement, 4 tips on how to pick winning stocks for your retirement share portfolio, This is the best asset to own to start saving for your early retirement, Commonwealth Bank of Australia (ASX: CBA), Flight Centre Travel Group Ltd (ASX: FLT), Vanguard Australian Shares Index (ASX: VAS). Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. });*/, Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, 10 Stocks To Buy (including 2 Every Investor Should Own), Setting Yourself Up for Success Before You Start. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. Recce Pharmaceuticals (ASX: ... a 17.5 per cent discount to the prevailing price ahead of a trading halt on October 7. This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria - ⦠Spurs U18 Table,
Read In Afrikaans,
Jets Calendar Chicago,
Bitcoin Atm In Iran,
Ashaya And Ancient Greenwarden,
" />
Current Trading Halts . July 6 (Reuters) - Recce Pharmaceuticals Ltd: * SEEKS TRADING HALT PENDING ANNOUNCEMENT ON MATERIAL RESEARCH AGREEMENT Source text ⦠Once trading resumed Recce Pharmaceuticals came out ⦠A positive result would most certainly lift the SP considerably and I don't think RCE would have trouble raising the capital needed for phase 2 studies. The rest of the trading day saw price remaining in the range of 3.30-3.33p. It seems fairly clear the trading halt is because they have recieved a response to the request for HREC approval to begin phase 1 trial of topical skin use. Learn about investing with our Investing Education hub. Quotes. Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program This represents a sizeable 20% discount to its last close price. ASX:RCE - Investor presentation, announcements, cashflow waterfall chart, news, capital raise history, & sector peers. Happy days! It’s been a big month for the company, being placed in a trading halt at the start of the month. Likes. This study tested the R327 and R529 drugs against the COVID-19 virus and results showed that both showed increasing efficacy as the doses increased. Our Top 5 Stocks for Investors 50 or Older – NOW AVAILABLE! You can do it. Individual Investor Institutional Investor Financial Advisor Active Trader. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. Recce’s Chief Executive Officer, James Graham, commented: “We greatly appreciate the support shown by both our existing investors and new institutional investors. Sector Healthcare RiskRating. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. Thank you! It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE ⦠Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Finally closing at 3.3p (-4.35% from Monday's closing price). The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising. Breaking News. event.preventDefault();
Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product; The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program All Instrument Types. The coming months will soon reveal whether investors were right to back this one. All Instrument Types. Quotes. Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. BRIEF-Recce Pharmaceuticals Ltd Seeks Trading Halt . The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from its trading halt on Tuesday and is shooting higher. Find the investing style that's right for you. Pause Threshold Price. They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. How Much Money Do I Need To Start Investing? The Motley Fool Australia operates under AFSL 400691. Investment news, stock ideas, and more, straight to your inbox. Recce Pharmaceuticals is up a healthy 3.06 per cent trading at $1.01; Reccce Pharamceuticals (RCE) has become a dual-lister after assuming its position on a major German exchange. BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement . Financial Services Guide | Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Recce Pharmaceuticals. Breaking News. Based on these results Recce has been advised it should advance research of both drugs.
document.querySelector(this.getAttribute('href')).scrollIntoView({ Hear our experts take on shares, the market & how to invest. This ensures it is fully funded to complete its Phase I human clinical trial, SARSCoV-2 (COVID-19) pre-clinical program, Helicobacter pylori preclinical program, and the anticipated Phase I/II topical study at a leading Australian teaching hospital. So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered! Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. /*document.querySelectorAll('a[href^="#"]').forEach(anchor => { Individual Investor Institutional Investor Financial Advisor Active Trader. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. The Motley Fool Australia does not guarantee the performance of, or returns on any investment. Read detailed company information and latest announcements from Recce Pharmaceuticals Ltd including news headlines & gain/loss. Despite its share price weakness today, the Recce share price is up over 360% since the start of the year. The approval is not to sell anything or to allow general use anywhere, it is purely the approval they have been waiting for to start this skin application trial. Juno Minerals (JNO), a new company made up of Jupiter Mines’ demerged iron ore assets, has made its debut on the ASX. REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria. Be the first with the news that moves the market, ASX Today: Rebound to continue despite ore dive, Infinity Lithium Corporation (ASX:INF) shares crash amid Spanish permit cancellation, The “gas-fired” investment opportunity in the Australian energy sector, Imugene (ASX:IMU) expands patent portfolio with City of Hope, Province Resources (ASX:PRL) enters trading halt ahead of fresh capital raise, AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract, Great Northern Minerals’ (ASX:GNM) shares jump on high-grade results from Camel Creek, Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising, The company's shares will remain paused until the earlier of September 23 or when the announcement is made, On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase 1 clinical study of its RECCE 327 antibiotic, REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria, This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327, Shares in Recce last traded for $1.64 on September 18. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. Home / Share Market News / Share Fallers / Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, James Mickleboro | September 23, 2020 12:29pm | More on: RCE. Itâs been a big month for the company, being placed in a trading halt at the start of the month. The company's shares will remain in a trading halt until the earlier of September 23, or when the announcement is made. Audeara (AUA) has finished its first full trading on the ASX, after carrying out a successful $7 million initial public offering (IPO). Terms of Service | Subscription Terms of Service, ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691, The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214, jQuery(document).on('click', 'a[href^="#"]', function (event) { Shares in Recce Pharmaceuticals are currently trading at A$1.11 and the price has moved by 0.127k% over the past 365 days. Equus Mining (EQE) has placed its shares in a trading halt while it plans an upcoming capital raising. Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials. Happy days! The Motley Fool has a disclosure policy. Our latest articles and strategies for the post-work life you want. On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme; Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13; Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute. RCE Share Price and Trading History RELATED STOCKHEAD STORIES
jQuery('html, body').animate({ Speculative. Past performance is not necessarily indicative of future returns. }); As trading continued in the morning, price bounced off of the 3.3p support twice. Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Join Our Premium Community The Complete Guide to Planning For Your Retirement, Setting up an SMSF: 10 Things You Need to Know Before Starting, 3 easy steps to building your ASX share portfolio for an early retirement, 4 tips on how to pick winning stocks for your retirement share portfolio, This is the best asset to own to start saving for your early retirement, Commonwealth Bank of Australia (ASX: CBA), Flight Centre Travel Group Ltd (ASX: FLT), Vanguard Australian Shares Index (ASX: VAS). Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. });*/, Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, 10 Stocks To Buy (including 2 Every Investor Should Own), Setting Yourself Up for Success Before You Start. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. Recce Pharmaceuticals (ASX: ... a 17.5 per cent discount to the prevailing price ahead of a trading halt on October 7. This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria - ⦠Spurs U18 Table,
Read In Afrikaans,
Jets Calendar Chicago,
Bitcoin Atm In Iran,
Ashaya And Ancient Greenwarden,
" />
Current Trading Halts . July 6 (Reuters) - Recce Pharmaceuticals Ltd: * SEEKS TRADING HALT PENDING ANNOUNCEMENT ON MATERIAL RESEARCH AGREEMENT Source text ⦠Once trading resumed Recce Pharmaceuticals came out ⦠A positive result would most certainly lift the SP considerably and I don't think RCE would have trouble raising the capital needed for phase 2 studies. The rest of the trading day saw price remaining in the range of 3.30-3.33p. It seems fairly clear the trading halt is because they have recieved a response to the request for HREC approval to begin phase 1 trial of topical skin use. Learn about investing with our Investing Education hub. Quotes. Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program This represents a sizeable 20% discount to its last close price. ASX:RCE - Investor presentation, announcements, cashflow waterfall chart, news, capital raise history, & sector peers. Happy days! It’s been a big month for the company, being placed in a trading halt at the start of the month. Likes. This study tested the R327 and R529 drugs against the COVID-19 virus and results showed that both showed increasing efficacy as the doses increased. Our Top 5 Stocks for Investors 50 or Older – NOW AVAILABLE! You can do it. Individual Investor Institutional Investor Financial Advisor Active Trader. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. Recce’s Chief Executive Officer, James Graham, commented: “We greatly appreciate the support shown by both our existing investors and new institutional investors. Sector Healthcare RiskRating. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. Thank you! It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE ⦠Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Finally closing at 3.3p (-4.35% from Monday's closing price). The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising. Breaking News. event.preventDefault(); Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product; The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program All Instrument Types. The coming months will soon reveal whether investors were right to back this one. All Instrument Types. Quotes. Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. BRIEF-Recce Pharmaceuticals Ltd Seeks Trading Halt . The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from its trading halt on Tuesday and is shooting higher. Find the investing style that's right for you. Pause Threshold Price. They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. How Much Money Do I Need To Start Investing? The Motley Fool Australia operates under AFSL 400691. Investment news, stock ideas, and more, straight to your inbox. Recce Pharmaceuticals is up a healthy 3.06 per cent trading at $1.01; Reccce Pharamceuticals (RCE) has become a dual-lister after assuming its position on a major German exchange. BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement . Financial Services Guide | Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Recce Pharmaceuticals. Breaking News. Based on these results Recce has been advised it should advance research of both drugs.
document.querySelector(this.getAttribute('href')).scrollIntoView({ Hear our experts take on shares, the market & how to invest. This ensures it is fully funded to complete its Phase I human clinical trial, SARSCoV-2 (COVID-19) pre-clinical program, Helicobacter pylori preclinical program, and the anticipated Phase I/II topical study at a leading Australian teaching hospital. So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered! Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. /*document.querySelectorAll('a[href^="#"]').forEach(anchor => { Individual Investor Institutional Investor Financial Advisor Active Trader. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. The Motley Fool Australia does not guarantee the performance of, or returns on any investment. Read detailed company information and latest announcements from Recce Pharmaceuticals Ltd including news headlines & gain/loss. Despite its share price weakness today, the Recce share price is up over 360% since the start of the year. The approval is not to sell anything or to allow general use anywhere, it is purely the approval they have been waiting for to start this skin application trial. Juno Minerals (JNO), a new company made up of Jupiter Mines’ demerged iron ore assets, has made its debut on the ASX. REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria. Be the first with the news that moves the market, ASX Today: Rebound to continue despite ore dive, Infinity Lithium Corporation (ASX:INF) shares crash amid Spanish permit cancellation, The “gas-fired” investment opportunity in the Australian energy sector, Imugene (ASX:IMU) expands patent portfolio with City of Hope, Province Resources (ASX:PRL) enters trading halt ahead of fresh capital raise, AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract, Great Northern Minerals’ (ASX:GNM) shares jump on high-grade results from Camel Creek, Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising, The company's shares will remain paused until the earlier of September 23 or when the announcement is made, On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase 1 clinical study of its RECCE 327 antibiotic, REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria, This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327, Shares in Recce last traded for $1.64 on September 18. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. Home / Share Market News / Share Fallers / Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, James Mickleboro | September 23, 2020 12:29pm | More on: RCE. Itâs been a big month for the company, being placed in a trading halt at the start of the month. The company's shares will remain in a trading halt until the earlier of September 23, or when the announcement is made. Audeara (AUA) has finished its first full trading on the ASX, after carrying out a successful $7 million initial public offering (IPO). Terms of Service | Subscription Terms of Service, ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691, The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214, jQuery(document).on('click', 'a[href^="#"]', function (event) { Shares in Recce Pharmaceuticals are currently trading at A$1.11 and the price has moved by 0.127k% over the past 365 days. Equus Mining (EQE) has placed its shares in a trading halt while it plans an upcoming capital raising. Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials. Happy days! The Motley Fool has a disclosure policy. Our latest articles and strategies for the post-work life you want. On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme; Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13; Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute. RCE Share Price and Trading History RELATED STOCKHEAD STORIES
jQuery('html, body').animate({ Speculative. Past performance is not necessarily indicative of future returns. }); As trading continued in the morning, price bounced off of the 3.3p support twice. Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Join Our Premium Community The Complete Guide to Planning For Your Retirement, Setting up an SMSF: 10 Things You Need to Know Before Starting, 3 easy steps to building your ASX share portfolio for an early retirement, 4 tips on how to pick winning stocks for your retirement share portfolio, This is the best asset to own to start saving for your early retirement, Commonwealth Bank of Australia (ASX: CBA), Flight Centre Travel Group Ltd (ASX: FLT), Vanguard Australian Shares Index (ASX: VAS). Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. });*/, Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, 10 Stocks To Buy (including 2 Every Investor Should Own), Setting Yourself Up for Success Before You Start. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. Recce Pharmaceuticals (ASX: ... a 17.5 per cent discount to the prevailing price ahead of a trading halt on October 7. This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria - â¦
